Search
Virginiamycin M1
go.drugbank.com/drugs/DB01669ExperimentalPristinamycin IIA is a macrolide antibiotic, a member of the streptogramin A group of antibiotics, and one component of pristinamycin. It is produced by Streptomyces graminofaciens and other bacteria.
PEV3A
go.drugbank.com/drugs/DB05144InvestigationalPEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302. The two synthetic peptide vaccine components...
IDD-3
go.drugbank.com/drugs/DB05427ExperimentalIDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. It includes Dendritophages that are den...
Aptazapine
go.drugbank.com/drugs/DB09305ExperimentalAptazapine (CGS-7525A) was a tetracyclic antidepressant developed in the 1980s. Aptazapine had noradrenergic and specific serotonergic activity. It antagonised α2 adrenergic receptors approximately 10 times more effectively than mianseri...
OSI-7836
go.drugbank.com/drugs/DB05837ExperimentalOSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader. OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. The anti-tumor activity of OSI-7836 appeares to be less sc...
Friulimicin B
go.drugbank.com/drugs/DB06087InvestigationalFriulimicin B is a naturally occurring antibiotic produced by a micro-organism, Actinoplanes friuliensis. It shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious infections in hospital pati...
Eldelumab
go.drugbank.com/drugs/DB06116InvestigationalMDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.
XR5944
go.drugbank.com/drugs/DB06364ExperimentalXR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.